Electromed, Inc.
$249.6K 11,742 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Purdue Pharmaceuticals L.P.
Purdue Pharmaceuticals L.P. reported $248,505.24 across General Payments, Research, and Ownership to 50 physicians and teaching hospitals across 50 transactions.
- $248.5K Above-median payer
- All-tracks total
- 50 Below-median volume
- Transactions
- 50 Below-median reach
- Recipients
- +$12.7K
- General Payments vs PY2023
Purdue Pharmaceuticals L.P. reported $248,505.24 across all CMS Open Payments tracks (General + Research + Ownership) to 50 physicians and teaching hospitals in Program Year 2024 - ranking #940 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $248,505.24, averaging $5.0K per recipient.
Purdue Pharmaceuticals L.P.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
11/100
Total payments
F
12/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer purdue-pharmaceuticals-l-p Purdue Pharmaceuticals L.P.
$248.5K · #940/1,925 · 0.0% industry · PY2024
- TOT $248.5K
- RANK #940
- SHARE 0.0%
- TXN 50
- RCP 50
- CAT 1
- GEN $248.5K
- ΔGEN +$12.7K
- TOP1 78.3%
- PY 2024
Volume peers
Nearest volume peer: Electromed, Inc. ($249.6K)
Purdue Pharmaceuticals L.P. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Purdue Pharmaceuticals L.P.'s CMS-reported General Payments increased by $12.7K (+5.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: PURDUE PHARMACEUTICALS L.P.PY2024: Purdue Pharmaceuticals L.P.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $235,813.32
- PY2024
- $248,505.24
What the Data Shows for Purdue Pharmaceuticals L.P.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Purdue Pharmaceuticals L.P. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 1-category general-payment breakdown below at $248.5K (100.0% of General Payments, 50 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 1 types of general payments, Purdue Pharmaceuticals L.P.'s largest category was "Consulting Fee" at $248.5K - 100.0% of General Payments.
How Purdue Pharmaceuticals L.P. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $248.5K | 50 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $248,505.24 (100.0%) of $248,505.24 in this company's General Payments records across 4 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Purdue Pharmaceuticals L.P.
The five named recipients with the highest reported General Payments from this company
- 1
Leslie Byrne
$194,495.30 across 25 reported transactions
- 2
Jolene S Spencer
$33,588.00 across 12 reported transactions
- 3
Margie Sander
$20,132.04 across 12 reported transactions
- 4
Karen Ellen Bohlen
$289.90 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Purdue Pharmaceuticals L.P. ranks #940 of 1,925 by total payments (top 49% by spend) but is notably more concentrated than that alone would suggest -- #251 of 1,838 by HHI (top 14% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- KARL STORZ SE & Co. KG : $39.6K total payments, HHI 6505
- Novocure GmbH : $19.1K total payments, HHI 6485
- Prolaio, Inc. : $8.5K total payments, HHI 6466
- Catalent Pharma Solutions, LLC : $6.3K total payments, HHI 6454
- Dutch Ophthalmic Research Center (International) B.V. : $12.1K total payments, HHI 6407
- Sealonix Inc. : $44.9K total payments, HHI 6380
- Purdue Pharmaceuticals L.P. (this company) : $248.5K total payments, HHI 6374
- Icometrix NV : $67.0K total payments, HHI 6364
- HNM Stainless, LLC : $4.2K total payments, HHI 6320
- Zealand Pharma A/S : $376.3K total payments, HHI 6299
- Vatech America, Inc. : $144.9K total payments, HHI 6293
- Aspen Surgical Products, Inc. : $47.1K total payments, HHI 6265
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Purdue Pharmaceuticals L.P.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Purdue Pharmaceuticals L.P..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Purdue Pharmaceuticals L.P..
Showing 6 of 1,924 companies with CMS-reported payment data.
Canon Medical Research USA Inc.
$247.3K 1 recipients
Compare payment profiles
Forestadent USA, Inc.
$247.1K 351 recipients
Compare payment profiles
Sentynl Therapeutics, Inc.
$245.9K 44 recipients
Compare payment profiles
Nico Corporation
$245.7K 49 recipients
Compare payment profiles
Elucent Medical
$251.3K 505 recipients
Compare payment profiles
Put this to use
Purdue Pharmaceuticals L.P. ranks #940 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Purdue Pharmaceuticals L.P.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.